ArticleNPJ breast cancer2026
Disparities in breast cancer incidence and survival by age, race, and molecular subtype in US women.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Using SEER datasets spanning nearly five decades, we identified a striking longitudinal shift in the breast cancer mortality burden from older to younger women, revealing an evolving risk landscape that warrant challenges to prevailing assumptions about age-related vulnerability. Leveraging contemporary data (2010-2022), we examined how molecular subtype, race, and age intersect jointly to shape survival disparities. As expected, young Black women with triple-negative breast cancer (HR-/HER2-) exhibited significantly elevated hazard ratios, underscoring their urgent need for targeted interventions and prevention strategies. Importantly, we also uncovered disproportionately high mortality risks among Asian women: those under 50 years experienced poorer outcomes for triple-negative breast cancer. These findings suggest that distinct biological, hormonal, and sociodemographic factors may contribute to heterogeneity in cancer progression and survival across populations. In addition, demographic analyses revealed that Asian and Hispanic women have steadily increased in proportional representation, surpassing Black patients recently, underscoring critical population shifts in the breast cancer burden. Together, these results not only broaden current understanding of how age, ancestry, and molecular subtype converge to drive disparities, but also underscore the urgent need to embed these dimensions into personalized prevention, precision diagnostics, and tailored therapeutic strategies to reduce inequities in breast cancer outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.